- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00834327
Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome
October 12, 2009 updated by: Neurogen Corporation
A Randomized, Double-Blind, Placebo-Controlled Four Week Study of the Efficacy and Safety of Four Doses (0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg) of Aplindore MR Tablets vs. Placebo in Idiopathic Restless Legs Syndrome.
This is a clinical trial to be conducted at multiple sites in the USA.
Patients diagnosed with moderate to severe Restless Legs Syndrome will be randomly allocated to one of 5 treatment arms in the study.
The 5 arms include 4 arms with different doses of aplindore MR tablets and 1 placebo arm.
The treatment will be taken once a day.
The study is blinded and neither patients, nor the investigators, will know what treatment the patient is receiving.
Patients will be assigned a dose and will be maintained at that dose for several weeks (2 treatment arms include a short titration period).
The entire study will take about 6 weeks.
The study will measure how effective aplindore is in decreasing symptoms of Restless Legs Syndrome, and will also assess the safety and tolerability of aplindore.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Two hundred and thirty patients will be randomly assigned to one of five treatment arms in this outpatient study.
Of the four aplindore arms, two arms will be titrated over a brief period until the targeted dose is achieved, and then as with the other arms, will be maintained for several weeks.
Dosing will take place over a total of about 4 weeks.
Study Type
Interventional
Enrollment (Anticipated)
230
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85050
- HOPE Research Institute
-
Tuscon, Arizona, United States, 85741
- Genova Clinical Research
-
-
California
-
Oceanside, California, United States, 92056
- Excell Research, Inc.
-
-
Colorado
-
Pueblo, Colorado, United States, 81001
- Lynn Institute of Pueblo
-
-
Connecticut
-
Wallingford, Connecticut, United States, 06492
- Gaylord Sleep Medicine
-
-
Florida
-
Clearwater, Florida, United States, 33761
- Tampa Bay Medical Research
-
Deland, Florida, United States, 32720
- University Clinical Research Deland, LLC
-
Hallandale Beach, Florida, United States, 33009
- MD Clinical
-
Pembroke Pines, Florida, United States, 33024
- University Clinical Research
-
Pembroke Pines, Florida, United States, 33026
- Broward Research Group
-
South Miami, Florida, United States, 33013
- Miami Research Associates
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- NeuroTrials Research, Inc.
-
-
Illinois
-
Vernon Hills, Illinois, United States, 60061
- Sleep & Behavior Medicine Institute
-
-
Kentucky
-
Crestview Hills, Kentucky, United States, 41017
- Community Research & Sleep Management Institute
-
-
Michigan
-
Bingham Farms, Michigan, United States, 48025
- QUEST Research Institute
-
-
Missouri
-
Chesterfield, Missouri, United States, 63017
- Sleep Medicine and Research Center - St Luke's Hospital
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Wake Research Associates
-
-
Ohio
-
Cincinnati, Ohio, United States, 45227
- Comunity Reasearch
-
Cincinnati, Ohio, United States, 45246
- Tri-State Sleep Disorders Center
-
Middleburg Heights, Ohio, United States, 44130
- North Star Medical Research, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Lynn Health Science Institute
-
-
South Carolina
-
Mt. Pleasant, South Carolina, United States, 29464
- Coastal Carolina Research Center
-
-
Texas
-
Dallas, Texas, United States, 75231
- Sleep Medicine Associates of Texas, P.A.
-
San Antonio, Texas, United States, 78229
- Paragon Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female 18-85 years;
- Must have a score of ≥20 on the IRLS at Day 1 (Baseline) Visit;
- Have a history of moderate to severe RLS symptoms that disrupted sleep for at least 3 nights per week over at least a 3 month period either immediately before screening or prior to starting any RLS treatment;
- Patients must be off dopamine agonists or any other medications they are taking for RLS for a minimum of one week or 5 half lives of the RLS medication whichever is longer, prior to the Day 1 (Baseline) Visit;
- Patients must be in good general health as determined by a thorough medical history and physical examination (including vital signs), and 12-lead electrocardiogram (ECG);
- Patients must have clinical laboratory values within normal reference range or must not be clinically significantly abnormal as judged by the Investigator at screening;
- Females of childbearing potential must be using an acceptable method of contraception, have a negative serum pregnancy test at screening, and a negative urine pregnancy test at baseline. Acceptable methods of contraception include oral, intrauterine, implantable, injectable contraceptives, hormonal patch, double barrier methods or condoms impregnated with spermicide. After screening, patients using oral contraceptive methods of contraception must agree to add an additional method until 30 days following the last dose of study medication. Women on oral contraceptives must have been using them for at least one month prior to screening;
- Male patients with partners of childbearing potential must agree to use adequate contraception (use of a condom and a spermicidal) during the study and for 3 months after the study;
- Female patients who have been surgically sterilized are eligible if they have a negative pregnancy test at screening and at Baseline;
- If receiving hormone replacement therapy, patients must be on a stable regimen for minimum of 3 months prior to screening;
- Patients must be able to read, understand, and provide written/dated informed consent before enrolling in the study, and must be willing to comply with all study procedures.
Exclusion Criteria:
- Clinically significant unstable medical illness;
- Clinically significant allergic, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease;
- History of non-basal cell cancer or squamous cell cancers or carcinoma in situ of the cervix within 2 years before the screening visit are excluded; for all other cancer diagnoses, patients with a history within 5 years before the screening visit are excluded;
- Patients with plasma ferritin levels less than 10 ng/mL at screening;
- A supine blood pressure > 140/90 mm/Hg at screening or baseline;
- Patients taking OTC or prescription medications that can, in the judgment of the investigator, exacerbate or are the cause of their RLS symptoms will be excluded from the study;
- Patients taking prescription drug therapy or over the counter (OTC) medication for chronic medical conditions other then RLS who are not on stable doses for at least two months prior to screening; patients who are not off any investigational drug for at least 30 days prior to screening;
- History of chronic use of dopamine antagonists for more than 6 months within the past 2 years;
- History or presence of chronic pain other than that associated with RLS. Patients should be excluded if the preponderance of the patient's complaints is related to pain and not associated with the urge to move;
- Clinically significant narcolepsy, parasomnia as an adult, significant circadian rhythm disorder, or secondary causes of RLS, (e.g., uremia or neuropathy);
- Any condition that may affect oral drug absorption;
- Travel across more than three time zones, have an expected change in sleep schedules of 6 hours or more, or have involvement in night shift work within seven days prior to screening through to study completion;
- Any clinically significant abnormal finding at the Screening Visit on physical examination, vital signs, or ECG, as determined by the Investigator; (The QTcF interval must be ≤ 450 msec for males and ≤ 470 msec for females);
- History of allergies, or known sensitivity, hypersensitivity, or adverse reaction to aplindore or structurally similar compounds such as flesinomax, ropinirole or ziprasadone;
- Pregnant or lactating females;
- Recent history (≤ one year) of alcohol or drug abuse, or current evidence of substance dependence or abuse as defined by DSM-IV criteria;
- Regular consumption of large amounts of xanthine-containing substances (i.e. more than 10 cups of coffee or equivalent amounts of xanthine-containing substances per day);
- Prior exposure to aplindore;
- Patients deemed to be in the high risk category for sleep apnea as determined by the Modified Berlin Questionnaire;
- Patients who failed prior treatment with dopamine agonists as evidenced by lack of efficacy at the maximum tolerated dose;
- Patients who test positive at Screening for hepatitis B surface antigen or hepatitis C antiboby or has a history of a positive result
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 5
Placebo
|
aplindore MR tablets administered QD for about 4 weeks
|
Experimental: 1
aplindore 0.05 mg MR total daily dose
|
aplindore MR tablets administered QD for about 4 weeks
|
Experimental: 2
aplindore 0.1 mg MR total daily dose
|
aplindore MR tablets administered QD for about 4 weeks
|
Experimental: 3
aplindore 0.25 mg MR total daily dose (to include short titration)
|
aplindore MR tablets administered QD for about 4 weeks
|
Experimental: 4
aplindore 0.5 mg MR total daily dose (to include short titration)
|
aplindore MR tablets administered QD for about 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change from baseline (Day 1) to final (Day 28) on the International Restless Legs Scale (IRLS).
Time Frame: Day 1, Day 14, and Day 28
|
Day 1, Day 14, and Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Primary Completion (Anticipated)
November 1, 2009
Study Completion (Anticipated)
December 1, 2009
Study Registration Dates
First Submitted
January 30, 2009
First Submitted That Met QC Criteria
January 30, 2009
First Posted (Estimate)
February 3, 2009
Study Record Updates
Last Update Posted (Estimate)
October 14, 2009
Last Update Submitted That Met QC Criteria
October 12, 2009
Last Verified
October 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Aplindore-250
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Restless Legs Syndrome
-
Walter Reed National Military Medical CenterWithdrawnEkbom Syndrome | Restless Legs Syndrome, | Restless Legs,United States
-
XenoPort, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs Syndrome
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
Astellas Pharma IncCompletedRestless Legs Syndrome (RLS)Japan
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan
-
UCB PharmaCompletedIdiopathic Restless Legs SyndromeGermany
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedIdiopathic Restless Legs SyndromeUnited States, Spain, Finland, Italy, Germany, Sweden, Austria, Netherlands, United Kingdom
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)
Clinical Trials on aplindore MR tablets or Placebo
-
Neurogen CorporationTerminatedEarly Parkinson DiseaseUnited States
-
Ligand PharmaceuticalsCompletedEarly Stage Parkinson's DiseaseUnited States
-
Ligand PharmaceuticalsCompletedRestless Legs SyndromeUnited States
-
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Not yet recruiting
-
Suzhou Kintor Pharmaceutical Inc,Terminated
-
PfizerCompleted
-
Disphar International B.V.WithdrawnComparative BioavailabilityJordan
-
Wuhan Union Hospital, ChinaRecruiting
-
BayerMerck Sharp & Dohme LLC; Duke Clinical Research Institute; Canadian VIGOUR CentreCompletedChronic Heart Failure With Preserved Ejection FractionSpain, United States, Belgium, Singapore, Taiwan, Canada, Japan, Italy, Austria, Bulgaria, Germany, Greece, Israel, Poland, Portugal, Hungary, Russian Federation, Argentina, Colombia, Malaysia, South Africa
-
Washington University School of MedicineCOVID -19 Therapeutics AcceleratorCompletedCOVID 19United States, South Africa, Ghana, United Kingdom, Zambia